Trial Profile
A Compassionate Use Study Assessing the Real-World Experience of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir with Ribavirin for Treatment of Recurrent Chronic Hepatitis C Genotype 1 Infection after Liver Transplantation in Taiwan
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Expanded access; Therapeutic Use
- 02 Nov 2018 New trial record